摘要
目的分析来氟米特联合胸腺肽治疗类风湿性关节炎患者的效果。方法选择35例类风湿性关节炎(RA)患者,应用来氟米特和胸腺肽联合治疗24周,治疗前和治疗12周、24周后评价患者的临床指标、实验室指标和治疗效果。结果治疗12周、24周后临床治疗的总有效率分别为88.6%和91.4%;在晨僵时间、关节肿胀数、关节压痛数、休息痛及握力等临床指标与用药前均有显著差异(P<0.01);在RF、ESR、CRP等实验室指标与用药前均有显著差异(P<0.01)。结论来氟米特联合胸腺肽治疗类风湿性关节炎安全有效。
Objective To analyze the effect of leflunomide plus thymosin in treatment of rheumatoid arthritis patients.Methods The 35 rheumatoid arthritis cases who were selected had been treated with leflunomide plus thymosin for 24 weeks.We evaluated their clinical markers,laboratory markers and treatment effect in pre-and post-therapy.Results Total utility rate was 88.6%(treating for 12 weeks) and 91.4%(treating for 24 weeks) as for clinical effect;There was more obvious difference(P0.01)in morning stiffness time,number of joint swelling,number of joint tenderness,rest pain and grasp force than pretherapy after 12-month and 24-month treatment;There was obvious difference(P0.01)in RF,ESR and CRP than pretherapy after 12-month and 24-month treatment.Conclusions Leflunomide plus thymosin is an effective and safe therapy for rheumatoid arthritis.
出处
《医药论坛杂志》
2012年第7期30-31,共2页
Journal of Medical Forum